Physician profile
Eskender Getachew
NPI 1033177571
$3,931.32
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $484 · 2021: $1,169 · 2022: $946 · 2023: $277 · 2024: $33.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $602.53 | 2022 | |
| Jazz Pharmaceuticals INC. | $489.57 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $307.87 | 2020-2021 | |
| Sk Life Science, INC. | $295.81 | 2020-2022 | |
| Biogen, INC. | $264.65 | 2019-2020 | |
| Merz North America, INC. | $186.97 | 2022-2023 | Xeomin |
| Eisai INC. | $175.24 | 2019 | |
| Galderma Laboratories, L.P. | $135.93 | 2021 | |
| Abbvie INC. | $126.43 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $124.83 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $123.78 | 2021-2024 | Contrave |
| Allergan, INC. | $117.57 | 2020-2022 | |
| Genzyme Corporation | $111.99 | 2019 | |
| Emd Serono, INC. | $99.81 | 2019-2021 | |
| Aprecia Pharmaceuticals, LLC | $80.64 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $76.02 | 2019-2020 | |
| Harmony Biosciences LLC | $68.53 | 2022 | |
| Fidia Pharma USA INC. | $67.49 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $57.39 | 2019 | |
| Pfizer INC. | $54.11 | 2023 | |
| Novartis Pharmaceuticals Corporation | $50.18 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $44.79 | 2019-2021 | |
| Celgene Corporation | $44.62 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $35.10 | 2019 | |
| Vertical Pharmaceuticals, LLC | $28.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.70 | 2019 | |
| Tanabe Pharma America, INC. | $20.81 | 2019 | |
| Amgen INC. | $19.67 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.96 | 2019 | |
| Acorda Therapeutics, INC | $15.93 | 2019 | |
| Zyla Life Sciences, INC. | $15.49 | 2019 | |
| Indivior INC. | $12.19 | 2019 | |
| Orexo US, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eskender Getachew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.